TrialBlood cancer journal2025

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.

Craig A Portell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.